Reimagining Alzheimer’s Disease: New Thinking, New Choices

Reimagining Alzheimer’s Disease: New Thinking, New Choices

Reimagining Alzheimer’s Disease: New Thinking, New Choices

Early diagnosis and newly available and emerging disease-modifying therapies for Alzheimer’s Disease (AD).

Available credits: 0.50


Valid until:

Take Post-Test

If you’ve already completed the activity.

  • Overview

    Alzheimer’s disease (AD) is an irreversible, age-related, neurodegenerative disorder characterized by gradual decline in understanding, memory, and ability to perform activities of daily living. It is the most common cause of dementia worldwide and its’ prevalence continues to grow in part because of the aging world population. AD is characterized classically by two hallmark pathologies: β-amyloid plaque deposition and neurofibrillary tangles of hyperphosphorylated tau. Diagnosis is based upon clinical presentation fulfilling several criteria including fluid and imaging biomarkers. Until recently, current therapies were limited to delaying cognitive decline in some patients, but not treating the underlying causes of the disease nor halting the progression of the disease. This program discusses recent advances in our understanding of the clinical evaluation for early and accurate diagnosis, newly approved and emerging disease-modifying therapies, as well as non-pharmacological strategies for the management of patients with AD.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Integrity and Independence and the University of Cincinnati policy, all faculty, planning committee members, and other individuals, who are in a position to control content, are required to disclose all relationships with ineligible companies (commercial interest) within the last 24-months. The ACCME requires us to disqualify individuals who refuse to provide this information from involvement in the planning and implementation of accredited continuing education. All educational materials are reviewed for fair balance, scientific objectivity, and levels of evidence.

    The following faculty has reported relationships with ineligible companies that have been mitigated:

    R. Scott Turner, MD, PhD has disclosed the following relevant financial relationships:
    Research Support to Georgetown: Biogen, Lilly, Eisai, Roche, Vaccinex, Janssen, Alector Therapeutics.
    Consultant: Jupiter Neurosciences, KeifeRx, Re:Cognition Health

    John J. Russell, MD (host) has disclosed the following relevant financial relationships:
    Speaker and Advisory Board Member: Bayer, GlaxoSmithKline, US Sanofi

    The following reviewers/planners/authors have reported no relationships with ineligible companies that have been mitigated:

    Susan Tyler, PhD, CME Director
    Robert Ellis, MD, CME Reviewer
    Heather Muskopf, Program Manager
    Otto Ratz, MD
    Christina Culbert, MSc

  • Target Audience

    The intended audiences for this activity are neurologists, psychiatrists, primary care physicians, geriatric physicians, and other health care professionals involved in the management of patients with Alzheimer’s Disease.

  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Incorporate the latest developments, particularly biomarker technology, for accurate, early detection, and proper diagnosis of AD;
    • Evaluate the therapeutic implications of emerging disease-modifying therapies and other late-state/newly approved strategies in the treatment of AD;
    • Integrate non-pharmaceutical interventions as part of a treatment plan to enhance outcomes for patients with AD.
  • Accreditation and Credit Designation Statements

    Accreditation Statement
    This CME activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Cincinnati and CORE Medical Education, LLC. University of Cincinnati is accredited by the ACCME to provide continuing medical education for physicians.

    Credit Designation
    University of Cincinnati designates this enduring material for a maximum of .5 AMA PRA Category 1 Credits™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    This CME activity was developed through the joint providership of the University of Cincinnati and CORE Medical Education, LLC.

  • Commercial Support

    This CME activity is supported by educational grants from Biogen and Lilly USA, LLC.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

Facebook Comments


We’re glad to see you’re enjoying Global Neurology Academy…
but how about a more personalized experience?

Register for free